

# Fabrice Andre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/380802/publications.pdf>

Version: 2024-02-01

498  
papers

67,333  
citations

967

118  
h-index

966

245  
g-index

525  
all docs

525  
docs citations

525  
times ranked

65437  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. <i>Clinical Cancer Research</i> , 2022, 28, 1412-1421.	3.2	46
2	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
4	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	0.8	23
5	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	2.3	67
6	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 <sup>+</sup> breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.4	2
7	Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). <i>Cancer Research</i> , 2022, 82, PD8-02-PD8-02.	0.4	68
8	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10
9	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022, 82, PD2-05-PD2-05.	0.4	2
10	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821.	0.8	23
11	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
12	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162.	0.8	18
13	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis Focus on proactive monitoring, diagnosis, and management. <i>Cancer Treatment Reviews</i> , 2022, 106, 102378.	3.4	60
14	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
15	Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France. <i>JAMA Network Open</i> , 2022, 5, e225118.	2.8	9
16	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	15.2	125
17	Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. <i>Analytical Chemistry</i> , 2022, 94, 6297-6303.	3.2	13
18	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	0.8	139

#	ARTICLE	IF	CITATIONS
19	Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. <i>Clinical Cancer Research</i> , 2022, 28, 2118-2130.	3.2	3
20	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	0.8	23
21	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 <sup>+</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	3.2	65
22	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 <sup>-</sup> Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	0.8	11
23	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. <i>EBioMedicine</i> , 2022, 80, 104077.	2.7	7
24	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	3.0	60
25	Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort. <i>Psycho-Oncology</i> , 2021, 30, 463-470.	1.0	5
26	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
27	AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia. <i>Medical Image Analysis</i> , 2021, 67, 101860.	7.0	111
28	Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2 <sup>-</sup> negative advanced breast cancer: final overall survival results from SOLAR-1. <i>Annals of Oncology</i> , 2021, 32, 208-217.	0.6	279
29	ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. <i>Annals of Oncology</i> , 2021, 32, 337-350.	0.6	76
30	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K <sup>Î±</sup> Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
31	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	2.7	113
32	Tribbles Pseudokinase 3 Regulation and Contribution to Cancer. <i>Cancers</i> , 2021, 13, 1822.	1.7	19
33	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	5.1	260
34	Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements. <i>Cancer</i> , 2021, 127, 2774-2787.	2.0	12
35	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
36	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021, 13, 87.	3.6	24

#	ARTICLE	IF	CITATIONS
37	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	5.0	72
38	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021, 28, 2276-2295.	5.0	18
39	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 741-769.	21.5	222
40	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021, 57, 43-48.	0.9	2
41	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021, 12, 599.	2.7	13
42	Patient-Reported Outcomes in Patients With <i>PIK3CA</i> -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	0.8	23
43	Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 448-448.	0.4	3
44	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	5.0	31
45	Alpelisib in combination with everolimus±Aromastane in solid tumours: Phase Ib randomised, open-label, multicentre study. <i>European Journal of Cancer</i> , 2021, 151, 49-62.	1.3	19
46	Determinants of use of oral complementary-alternative medicine among women with early breast cancer: A focus on cancer-related fatigue. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 517-529.	1.1	9
47	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
48	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIRO2-BREAST IMMUNO trial. <i>Nature Medicine</i> , 2021, 27, 250-255.	15.2	85
49	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9
50	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	3.4	66
51	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	1.3	9
52	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , 2021, 159, 283-295.	1.3	24
53	Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 98-110.	2.3	3
54	Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 387-401.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Reply to A. Katz. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-103.	0.8	0
56	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	3.2	114
57	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020, 38, 734-743.	0.8	69
58	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	13.9	1,143
59	Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association Data. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa039.	1.4	9
60	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
61	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
62	Progresses Toward Precision Medicine in <i>RET</i> -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6102-6111.	3.2	39
63	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020, 33, 108421.	2.9	77
64	Body weight and return to work among survivors of early-stage breast cancer. <i>ESMO Open</i> , 2020, 5, e000908.	2.0	9
65	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
66	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	13.5	663
67	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	13.7	221
68	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	5.7	98
69	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	2.3	16
70	Immune responses during COVID-19 infection. <i>OncImmunology</i> , 2020, 9, 1807836.	2.1	103
71	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	6.0	217
72	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1001-1010.	0.6	99

#	ARTICLE	IF	CITATIONS
73	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
74	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	1.3	53
75	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
76	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772.	0.8	80
77	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100023.	0.6	11
78	The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. <i>Cancer Research</i> , 2020, 80, 3062-3069.	0.4	8
79	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.4	4
80	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	6.3	260
81	Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1759-1766.	1.1	18
82	Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 377-386.	0.6	173
83	Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020, 10, 526-535.	7.7	36
84	A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19 positive patients with cancer. <i>European Journal of Cancer</i> , 2020, 132, 1-4.	1.3	20
85	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	0.8	353
86	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 763-775.	5.1	144
87	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020, 52, 23-32.	0.9	15
88	Lucitanib for the Treatment of HR+/HER2 <sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
89	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
90	Self-supervised Nuclei Segmentation in Histopathological Images Using Attention. <i>Lecture Notes in Computer Science</i> , 2020, , 393-402.	1.0	27

#	ARTICLE	IF	CITATIONS
91	Ribosomal RNA 2â€²O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. <i>NAR Cancer</i> , 2020, 2, zcaa036.	1.6	40
92	Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. <i>Cancer Research</i> , 2020, 80, CT403-CT403.	0.4	25
93	Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01). , 2020, , .		6
94	Abstract GS3-02: Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIRO2-IMMUNO. , 2020, , .		9
95	Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigatorâ€™s choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02). <i>Cancer Research</i> , 2020, 80, OT1-07-04-OT1-07-04.	0.4	3
96	Abstract P2-13-03: Lifestyle changes after breast cancer: A prospective study among 8580 women. , 2020, , .		1
97	Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study. <i>Cancer Research</i> , 2020, 80, P4-10-04-P4-10-04.	0.4	7
98	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.4	34
99	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43.	1.8	107
100	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1009-1009.	0.8	34
101	Abstract P6-11-07: Impact of chemotherapy on the health related quality of life among elderly patients with localized breast cancer: Findings from the prospective CANTO cohort. , 2020, , .		0
102	Abstract 1114: Novel preclinical models of aggressive variants of castration-resistant prostate cancer. , 2020, , .		0
103	Abstract P3-11-10: Health-related quality of life (HRQoL) in monarchER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer. , 2020, , .		0
104	Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts). <i>European Journal of Cancer</i> , 2020, 138, S92.	1.3	0
105	Alpelisib for <i>PIK3CA</i>-Mutated Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 686-687.	13.9	15
106	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 495-497.	2.5	9
107	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. <i>Annals of Oncology</i> , 2019, 30, 1417-1427.	0.6	263
108	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Annals of Oncology</i> , 2019, 30, 1784-1795.	0.6	138

#	ARTICLE	IF	CITATIONS
109	Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23691-23697.	3.3	32
110	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry, 2019, 65, 1405-1413.	1.5	53
111	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2019, 30, 365-373.	0.6	106
112	A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 743-753.	1.1	15
113	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Updateâ€”Integration of Results From TAILORx. Journal of Clinical Oncology, 2019, 37, 1956-1964.	0.8	189
114	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet, The, 2019, 393, 2591-2598.	6.3	102
115	Genomic characterization of metastatic breast cancers. Nature, 2019, 569, 560-564.	13.7	448
116	Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptorâ€”Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940.	13.9	1,582
117	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
118	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Annals of Oncology, 2019, 30, 1232-1243.	0.6	614
119	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. Cancer Medicine, 2019, 8, 2535-2544.	1.3	26
120	T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Annals of Oncology, 2019, 30, 934-944.	0.6	20
121	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
122	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€”Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	0.8	266
123	News from the San Antonio Breast Cancer Symposium 2018. Breast Care, 2019, 14, 60-62.	0.8	0
124	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€”2 trial. Lancet Oncology, The, 2019, 20, 371-382.	5.1	327
125	UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open, 2019, 4, e000562.	2.0	53
126	NEXT GENERATION SEQUENCING FOR CLINICAL DECISIONS: FRIEND OR FOE. Breast, 2019, 48, S23.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Efficacy of PI3K inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2019, 30, x12-x20.	0.6	145
128	Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002989.	3.9	47
129	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019, 30, 1941-1949.	0.6	155
130	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. <i>Nature Communications</i> , 2019, 10, 5713.	5.8	70
131	Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline <i>PTEN</i> Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	10
132	A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPESIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2- ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR. <i>Breast</i> , 2019, 48, S48.	0.9	0
133	Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 573-583.	1.1	13
134	Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation. , 2019, , .		2
135	Abstract CT142: Prevalence of <i>PIK3CA</i> mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial. <i>Cancer Research</i> , 2019, 79, CT142-CT142.	0.4	11
136	RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1092-1092.	0.8	20
137	Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 512-512.	0.8	2
138	Cognitive impairment in breast cancer patients before surgery?: Results of a subgroup of the French CANTO cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 561-561.	0.8	2
139	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS601-TPS601.	0.8	10
140	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3159-TPS3159.	0.8	0
141	Abstract 1929: Establishment, molecular and pharmacological profiling of novel prostate cancer-derived xenografts from patients with advanced, treatment-refractory, disease to identify resistance mechanisms and new therapeutic options. , 2019, , .		0
142	Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer. , 2019, , .		0
143	Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study. , 2019, , .		0
144	Abstract 2122: Generation of a fully characterized preclinical PDX panel to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	Developing Anticancer Drugs in Orphan Molecular Entities " A Paradigm under Construction. New England Journal of Medicine, 2018, 378, 763-765.	13.9	18
146	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	1.3	14
147	Funding sources of practice-changing trials. Annals of Oncology, 2018, 29, 1063-1065.	0.6	8
148	Annals of Oncology: factors for making a real impact. Annals of Oncology, 2018, 29, 28-29.	0.6	2
149	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 2018, 29, 640-645.	0.6	245
150	Reply to "The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.. Annals of Oncology, 2018, 29, 281-282.	0.6	3
151	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology, 2018, 29, 30-35.	0.6	118
152	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	3.2	26
153	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology, 2018, 29, 162-169.	0.6	46
154	American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond"Lessons Learned and Member Institutions" Perspectives. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	1.0	33
155	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018, 379, 1926-1936.	13.9	805
156	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery, 2018, 8, 1390-1403.	7.7	397
157	4th ESO"ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 2018, 29, 1634-1657.	0.6	891
158	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
159	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer Journal (Sudbury, Mass ), 2018, 24, 153-162.	1.0	17
160	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Annals of Oncology, 2018, 29, 1755-1762.	0.6	42
161	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. Cell Cycle, 2018, 17, 605-615.	1.3	21
162	Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial. , 2018, , .		17

#	ARTICLE	IF	CITATIONS
163	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1115-TPS1115.	0.8	3
164	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
165	Abstract 2953: Overall survival results of the single-institution molecular screening MOSCATO trial in hard-to-treat advanced cancers. , 2018, , .		0
166	Abstract 2524: A new mTOR-independent effect of rapamycin: Transcriptional regulation of TRIB3. , 2018, , .		0
167	Abstract 2147: Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies. , 2018, , .		1
168	Evaluation of BCGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal of Clinical Oncology, 2017, 35, 157-165.	0.8	345
169	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2 <sup>+</sup> breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research, 2017, 19, 18.	2.2	87
170	Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. Annals of Oncology, 2017, 28, 1145-1151.	0.6	18
171	Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?. European Journal of Cancer, 2017, 77, 153-154.	1.3	0
172	3rd ESO <sup>®</sup> ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	0.6	865
173	Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment. Annals of Oncology, 2017, 28, 1167-1168.	0.6	6
174	AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery, 2017, 7, 818-831.	7.7	1,235
175	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research, 2017, 23, 5366-5373.	3.2	109
176	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
177	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet, The, 2017, 389, 2403-2414.	6.3	168
178	3rd ESO <sup>®</sup> ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	0.9	171
179	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European Journal of Cancer, 2017, 86, 257-265.	1.3	31
180	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non <sup>®</sup> Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530

#	ARTICLE	IF	CITATIONS
181	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
182	Defining research priorities without biases: what is the optimal process?. <i>Annals of Oncology</i> , 2017, 28, 195-196.	0.6	4
183	Multigene Testing: Aid or Clinical Nightmare. <i>Breast</i> , 2017, 36, S26.	0.9	0
184	Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment. <i>Results and Problems in Cell Differentiation</i> , 2017, 64, 283-290.	0.2	19
185	Characteristics of the Metastatic Breast Cancer Population with PIK3CA Mutation in the Randomized Phase II Study SAFIRO2 Breast (UCBG-0105/1304). <i>Breast</i> , 2017, 36, S44.	0.9	0
186	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017, 22, 1028-1038.	1.9	108
187	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017, 28, 103-109.	0.6	52
188	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188174.	1.1	85
189	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	0.6	844
190	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2838-2847.	0.8	241
191	Abstract 1008: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. <i>Cancer Research</i> , 2017, 77, 1008-1008.	0.4	10
192	Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers. <i>Cancer Research</i> , 2017, 77, CT045-CT045.	0.4	11
193	Abstract LB-102: Landscape analysis of the initial data release from AACR Project GENIE. , 2017, , .		1
194	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10069-10069.	0.8	1
195	A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarchHER).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1109-TPS1109.	0.8	3
196	A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1111-TPS1111.	0.8	6
197	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1117-TPS1117.	0.8	11
198	UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS10125-TPS10125.	0.8	0

#	ARTICLE	IF	CITATIONS
199	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 575-575.	0.8	1
200	Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies. , 2017, , .		0
201	Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study. <i>Cancer Research</i> , 2017, 77, LB-103-LB-103.	0.4	6
202	Abstract 5461: Nuclear localization of the caspase 3 cleaved form of p73 in anoikis. , 2017, , .		0
203	A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2035.	1.8	56
204	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002201.	3.9	300
205	Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 5983-5991.	3.2	124
206	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. <i>Clinical and Translational Science</i> , 2016, 9, 283-292.	1.5	36
207	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016, 27, 1443-1448.	0.6	79
208	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016, 34, 2115-2124.	0.8	141
209	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , 2016, 22, 464-471.	15.2	83
210	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137.	1.3	33
211	Reply to D.C. SgROI et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3946-3948.	0.8	3
212	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
213	The ratio of CD8 <sup>+</sup> /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmmunology</i> , 2016, 5, e1218106.	2.1	50
214	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016, 76, 5954-5961.	0.4	16
215	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	0.8	573
216	Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. <i>Annals of Oncology</i> , 2016, 27, 1047-1054.	0.6	133

#	ARTICLE	IF	CITATIONS
217	Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein. <i>Oncologie</i> , 2016, 18, 103-108.	0.2	1
218	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	3.2	103
219	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
220	rCGH: a comprehensive array-based genomic profile platform for precision medicine. <i>Bioinformatics</i> , 2016, 32, 1402-1404.	1.8	15
221	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). <i>European Journal of Cancer</i> , 2016, 59, 79-89.	1.3	36
222	Statistical controversies in clinical research: statistical significance "too much of a good thing". <i>Annals of Oncology</i> , 2016, 27, 760-762.	0.6	10
223	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
224	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. <i>Cell Cycle</i> , 2016, 15, 295-302.	1.3	23
225	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. <i>Journal of Thoracic Oncology</i> , 2016, 11, e21-e23.	0.5	8
226	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 21-32.	1.1	38
227	Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. <i>Oncolimmunology</i> , 2016, 5, e1082706.	2.1	45
228	Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial. , 2016, , .		10
229	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. , 2016, , .		7
230	Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials. , 2016, , .		1
231	Dendritic cell-derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 1224-1232.	3.9	427
232	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 512-512.	0.8	17
233	Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy " results from Paloma-3.. <i>Journal of Clinical Oncology</i> , 2016, 34, 524-524.	0.8	8
234	SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2 advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS618-TPS618.	0.8	13

#	ARTICLE	IF	CITATIONS
235	Nuclear localization of the caspase-3-cleaved form of p73 in anoikis. <i>Oncotarget</i> , 2016, 7, 12331-12343.	0.8	4
236	Abstract LB-353: Mutational profile of metastatic breast cancers using whole-exome sequencing: a retrospective analysis of 216 samples from SAFIRO1 / 02 / SHIVA / MOSCATO trials. , 2016, , .		0
237	Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial. <i>Cancer Research</i> , 2016, 76, CT020-CT020.	0.4	2
238	Abstract 1832: Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey. , 2016, , .		0
239	IN12 THE ROLE OF CDK AND PI3K/MTOR INHIBITORS. <i>Breast</i> , 2015, 24, S25.	0.9	0
240	Patterns of resource utilization and cost for postmenopausal women with hormone-receptorâ€“positive, human epidermal growth factor receptor-2â€“negative advanced breast cancer in Europe. <i>BMC Cancer</i> , 2015, 15, 787.	1.1	6
241	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. <i>BMC Medical Genomics</i> , 2015, 8, 58.	0.7	49
242	Precision Medicine for Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e2-e7.	1.8	14
243	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	13.9	1,239
244	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€“Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	0.8	863
245	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1698-1704.	0.6	244
246	Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 1-8.	1.1	122
247	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4
248	Bevacizumab: the phoenix of breast oncology?. <i>Lancet Oncology</i> , The, 2015, 16, 600-601.	5.1	8
249	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 816-829.	5.1	261
250	Precision medicine for metastatic breast cancerâ€“limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
251	Targeting FGFR Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2684-2694.	3.2	399
252	Adapting the drivers to the road: a new strategy for cancer evolution?. <i>Annals of Oncology</i> , 2015, 26, 827-829.	0.6	5

#	ARTICLE	IF	CITATIONS
253	Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles. <i>European Journal of Cancer</i> , 2015, 51, 791-799.	1.3	83
254	Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
255	Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology. <i>Annals of Oncology</i> , 2015, 26, 582-588.	0.6	13
256	Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHOA. <i>Breast</i> , 2015, 24, 376-383.	0.9	15
257	Ki67 – no evidence for its use in node-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 296-301.	12.5	58
258	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367
259	Targeted therapies for ER+/HER2- metastatic breast cancer. <i>BMC Medicine</i> , 2015, 13, 137.	2.3	59
260	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015, 21, 1128-1138.	15.2	268
261	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. <i>Annals of Oncology</i> , 2015, 26, 2073-2078.	0.6	271
262	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
263	Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. <i>Cancer Research</i> , 2015, 75, S6-01-S6-01.	0.4	9
264	Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 108-108.	0.8	2
265	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 511-511.	0.8	5
266	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2015, 33, 512-512.	0.8	8
267	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). <i>Journal of Clinical Oncology</i> , 2015, 33, 613-613.	0.8	1
268	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA502-LBA502.	0.8	12
269	Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT)., 2015, , .		0
270	Abstract P3-06-07: Alterations of intratumoral signalling in breast cancer patients receiving pre-operative trastuzumab alone or combined with everolimus. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
271	Abstract OT1-1-03: Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer (INES). , 2015, , .		0
272	Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project. , 2015, , .		1
273	Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. , 2015, , .		0
274	Abstract 381: Circulating tumor cells (CTC) but not circulating endothelial cells (CEC) are independent prognostic factors in neoadjuvant chemotherapy combined with bevacizumab in HER2 negative inflammatory breast cancer (IBC) in multicentre phase II trial BEVERLY1. , 2015, , .		0
275	Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Research, 2015, 35, 5179-84.	0.5	22
276	The Horizon of Precision Medicine in Breast Cancer: Fragmentation, Alliance, or Reunification?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e5-e10.	1.8	5
277	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clinical Cancer Research, 2014, 20, 456-468.	3.2	153
278	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology, 2014, 25, 2244-2251.	0.6	153
279	Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. Annals of Oncology, 2014, 25, 917-918.	0.6	5
280	Reproducible, innovative, global and balanced: the pillars for manuscript acceptance at Annals of Oncology. Annals of Oncology, 2014, 25, 759-760.	0.6	1
281	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Annals of Oncology, 2014, 25, 763-773.	0.6	67
282	Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Current Medical Research and Opinion, 2014, 30, 1007-1016.	0.9	42
283	Prioritizing targets for precision cancer medicine. Annals of Oncology, 2014, 25, 2295-2303.	0.6	146
284	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology, 2014, 25, 1871-1888.	0.6	402
285	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biology, 2014, 15, 433.	3.8	69
286	Genomes in the clinic: the Gustave Roussy Cancer Center experience. Current Opinion in Genetics and Development, 2014, 24, 99-106.	1.5	10
287	Decision-making from multidisciplinary team meetings to the bedside: Factors influencing the recruitment of breast cancer patients into clinical trials. Breast, 2014, 23, 170-174.	0.9	8
288	<i>TP53</i> mutationâ€correlated genes predict the risk of tumor relapse and identify <i>MPS1</i> as a potential therapeutic kinase in <i>TP53</i> â€mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	2.1	59

#	ARTICLE	IF	CITATIONS
289	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	5.1	434
290	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. <i>Journal of Pathology</i> , 2014, 232, 274-282.	2.1	48
291	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	0.9	269
292	Clinical development of mTOR inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 203.	2.2	49
293	Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014, 16, 205.	2.2	56
294	Cancer cellâ€œautonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
295	BOLERO-3 results: pharmacological activity or pharmacokinetic effect? â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2014, 15, e304-e305.	5.1	1
296	Dendritic Cellâ€œDerived Exosomes as Immunotherapies in the Fight against Cancer. <i>Journal of Immunology</i> , 2014, 193, 1006-1011.	0.4	231
297	<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Antiâ€œHuman Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3212-3220.	0.8	231
298	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. <i>BMC Medicine</i> , 2014, 12, 132.	2.3	65
299	Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€œPositive, Locally Advanced, or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1437-1444.	0.8	72
300	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51
301	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	5.1	351
302	Chk1 as a new therapeutic target in triple-negative breast cancer. <i>Breast</i> , 2014, 23, 250-258.	0.9	50
303	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014, 25, 611-618.	0.6	359
304	Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. <i>Cell Death and Differentiation</i> , 2014, 21, 69-78.	5.0	191
305	Abstract 435: Is PYGM dysregulation involved in breast cancer cell metabolism. , 2014, , .		1
306	Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. , 2014, , .		11

#	ARTICLE	IF	CITATIONS
307	Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 11010-11010.	0.8	11
308	A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.. Journal of Clinical Oncology, 2014, 32, 8035-8035.	0.8	27
309	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1134-TPS1134.	0.8	2
310	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. Journal of Clinical Oncology, 2014, 32, 1082-1082.	0.8	0
311	Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials.. Journal of Clinical Oncology, 2014, 32, 11087-11087.	0.8	1
312	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. Journal of Clinical Oncology, 2014, 32, 2565-2565.	0.8	0
313	Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients.. Journal of Clinical Oncology, 2014, 32, 11057-11057.	0.8	0
314	Abstract 896: Serum-vascular endothelial growth factors (sVEGF) A and C have a potential as predictive tests for neoadjuvant bevacizumab in primary breast cancer. , 2014, , .		0
315	Abstract 2481: Complex deregulation of p73 transcripts in breast tissues: overexpression in benign breast fibroadenomas, and down-regulation in breast cancers. , 2014, , .		0
316	ecancermedalscience. Ecancermedalscience, 2013, 7, 299.	0.6	17
317	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, 2013, 32, 5377-5387.	2.6	83
318	Gene copy number variations in breast cancer of Sub-Saharan African women. Breast, 2013, 22, 295-300.	0.9	8
319	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
320	Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non-“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 2167-2172.	0.8	170
321	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2013, 141, 437-446.	1.1	70
322	Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. Clinical Cancer Research, 2013, 19, 28-33.	3.2	173
323	Outcome in breast molecular subtypes according to nodal status and surgical procedures. American Journal of Surgery, 2013, 205, 662-667.	0.9	43
324	PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs. Lung Cancer, 2013, 80, 216-222.	0.9	40

#	ARTICLE	IF	CITATIONS
325	19q13-ERCC1 Gene Copy Number Increase in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 549-557.	1.1	9
326	Quantification of residual risk of relapse in breast cancer patients optimally treated. <i>Breast</i> , 2013, 22, S92-S95.	0.9	16
327	Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis. <i>Cancer Research</i> , 2013, 73, 2418-2427.	0.4	255
328	Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives. <i>Cancer Discovery</i> , 2013, 3, 264-279.	7.7	339
329	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	13.9	342
330	Landscape and evolution of therapeutic research for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 319-324.	1.1	3
331	mTOR inhibitors in advanced breast cancer: Ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013, 39, 742-752.	3.4	27
332	What can be done for patients with NSCLC without druggable targets?. <i>Lancet Oncology</i> , The, 2013, 14, 191-192.	5.1	1
333	Retinoic Acid Receptor Alpha Amplifications and Retinoic Acid Sensitivity in Breast Cancers. <i>Clinical Breast Cancer</i> , 2013, 13, 401-408.	1.1	15
334	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013, 14, 931-939.	0.6	43
335	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1719-1725.	0.8	247
336	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. <i>Oncologist</i> , 2013, 18, 1063-1073.	1.9	75
337	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3693-3702.	3.2	270
338	Distinct tumor protein p53 mutants in breast cancer subgroups. <i>International Journal of Cancer</i> , 2013, 132, 1227-1231.	2.3	88
339	ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics. <i>Cancer Research</i> , 2013, 73, 2905-2915.	0.4	56
340	Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2273-2281.	0.8	276
341	Issues in clinical research for metastatic breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 625-629.	1.1	7
342	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013, 24, 647-654.	0.6	117

#	ARTICLE	IF	CITATIONS
343	Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. <i>Cancer Research</i> , 2013, 73, 2247-2258.	0.4	86
344	New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 587-593.	1.1	11
345	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. <i>Cell Cycle</i> , 2013, 12, 3298-3306.	1.3	37
346	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. <i>Clinical Cancer Research</i> , 2013, 19, 4315-4325.	3.2	32
347	Reproducibility of research and preclinical validation: problems and solutions. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 720-724.	12.5	83
348	Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .. <i>Cancer Research</i> , 2013, 73, LB-145-LB-145.	0.4	33
349	Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial Interim results.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2512-2512.	0.8	21
350	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , 2013, 31, 505-505.	0.8	34
351	Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIRO1).. <i>Journal of Clinical Oncology</i> , 2013, 31, 511-511.	0.8	8
352	Abstract 1470: Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small cell lung cancer.. , 2013, , .		0
353	Abstract 617: High-throughput screens identify PARP inhibition as being synthetically lethal with ERCC1 deficiency in non-small cell lung cancer cell lines.. , 2013, , .		0
354	Abstract 630: ERCC1-202 isoform is responsible for all known functions of ERCC1.. , 2013, , .		0
355	Abstract 1220: PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. , 2013, , .		0
356	Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS651-TPS651.	0.8	1
357	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11061-11061.	0.8	1
358	Abstract CN02-02: From precision medicine to personalized medicine in metastatic breast cancer patients.. , 2013, , .		0
359	Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy.. , 2013, , .		0
360	Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. <i>Annals of Oncology</i> , 2012, 23, 2059-2064.	0.6	12

#	ARTICLE	IF	CITATIONS
361	Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. <i>Annals of Oncology</i> , 2012, 23, 2245-2252.	0.6	60
362	DNA Repair Capacity in Circulating Lymphocytes and Influence on Platinum Effect in Tumor Cells. <i>Journal of Clinical Oncology</i> , 2012, 30, 1567-1568.	0.8	2
363	Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups. <i>Clinical Cancer Research</i> , 2012, 18, 1555-1560.	3.2	27
364	Triple-negative breast cancer: are we making headway at least?. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 195-210.	1.4	75
365	A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. <i>British Journal of Cancer</i> , 2012, 106, 1107-1116.	2.9	41
366	Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 2046-2052.	0.6	34
367	mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. <i>Annals of Oncology</i> , 2012, 23, 2526-2535.	0.6	45
368	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1996-2004.	0.8	194
369	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. <i>Annals of Oncology</i> , 2012, 23, 2997-3006.	0.6	233
370	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , 2012, 7, 267-272.	0.8	12
371	Conference Scene: Advances in breast cancer translational research. <i>Breast Cancer Management</i> , 2012, 1, 197-199.	0.2	0
372	Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, e58-e69.	2.0	10
373	Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 2293-2299.	1.3	21
374	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. <i>Annals of Oncology</i> , 2012, 23, vi46-vi51.	0.6	236
375	Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. <i>Human Pathology</i> , 2012, 43, 1932-1939.	1.1	5
376	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 301-313.	2.0	76
377	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. <i>Molecular Oncology</i> , 2012, 6, 204-210.	2.1	18
378	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. <i>Science Translational Medicine</i> , 2012, 4, 143ra99.	5.8	367

#	ARTICLE	IF	CITATIONS
379	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 895-915.	1.1	246
380	Interpathologists discrepancies in Ki67 assessment in the PACS01 trial: An independent prognosis factor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 543-543.	0.8	1
381	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1607-1614.	0.4	105
382	Implications of personalized medicineâ€™ perspective from a cancer center. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 177-183.	12.5	52
383	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 171-176.	12.5	106
384	Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues. <i>European Journal of Cancer</i> , 2011, 47, 2249-2255.	1.3	42
385	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. <i>Breast Cancer Research</i> , 2011, 13, R109.	2.2	24
386	Tumor genotyping for breast cancer: at the front door. <i>Personalized Medicine</i> , 2011, 8, 383-385.	0.8	0
387	Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 195-205.	2.0	22
388	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 264-272.	3.0	203
389	Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1236-1238.	0.8	65
390	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 2591-2601.	3.2	52
391	A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. <i>British Journal of Cancer</i> , 2011, 105, 847-853.	2.9	369
392	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. <i>Clinical Cancer Research</i> , 2011, 17, 5562-5572.	3.2	56
393	ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. <i>Annals of Oncology</i> , 2011, 22, 575-581.	0.6	15
394	Abstract 1623: The spliceosome as a new therapeutic target for anticancer treatment. , 2011, , .		0
395	Abstract 2225: First double validation of transcription infidelity biomarkers for breast cancer diagnosis. , 2011, , .		0
396	Abstract 581: Gene-expression signatures of anoikis induced by doxorubicin, docetaxel or transfection with TAp73Î±. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
397	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 341-345.	0.6	39
398	Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. <i>Current Opinion in Oncology</i> , 2010, 22, 547-551.	1.1	51
399	Traitements mÃ©dicaments par la biologie en pathologie mammaire. <i>Oncologie</i> , 2010, 12, 274-277.	0.2	1
400	Breast Cancer Classification to Select Patients for Cancer Treatment. <i>Current Breast Cancer Reports</i> , 2010, 2, 152-158.	0.5	0
401	Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 747-755.	1.1	44
402	Characteristics, Treatment, and Outcome of Breast Cancers Diagnosed in BRCA1 and BRCA2 Gene Mutation Carriers in Intensive Screening Programs Including Magnetic Resonance Imaging. <i>Clinical Breast Cancer</i> , 2010, 10, 113-118.	1.1	22
403	Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 187-191.	1.1	25
404	A nomogram to predict for malignant diagnosis of BI-RADS category 4 breast lesions. <i>Journal of Surgical Oncology</i> , 2010, 102, 220-224.	0.8	8
405	Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. <i>Proteomics</i> , 2010, 10, 3525-3532.	1.3	19
406	Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. <i>British Journal of Cancer</i> , 2010, 102, 462-468.	2.9	37
407	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 367-380.	12.5	94
408	Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. <i>Oncologist</i> , 2010, 15, 476-483.	1.9	6
409	Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands. <i>Cancer Research</i> , 2010, 70, 490-500.	0.4	104
410	Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. <i>Annals of Oncology</i> , 2010, 21, vii30-vii35.	0.6	92
411	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2010, 28, 5110-5115.	0.8	203
412	Integration of Host-Related Signatures with Cancer Cell-Derived Predictors for the Optimal Management of Anticancer Chemotherapy. <i>Cancer Research</i> , 2010, 70, 9538-9543.	0.4	27
413	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4316-4323.	0.8	193
414	First-generation genomic tests for breast cancer treatment. <i>Lancet Oncology</i> , The, 2010, 11, 6-7.	5.1	12

#	ARTICLE	IF	CITATIONS
415	Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4111-4119.	0.8	235
416	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. <i>Genome Medicine</i> , 2010, 2, 53.	3.6	43
417	Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers. <i>Oncologist</i> , 2010, 15, 246-252.	1.9	47
418	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. <i>Oncologist</i> , 2009, 14, 1182-1188.	1.9	59
419	Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4287-4292.	0.8	81
420	Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2809-2815.	0.8	214
421	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. <i>Clinical Cancer Research</i> , 2009, 15, 441-451.	3.2	300
422	P53 Family: At the Crossroads in Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2009, 16, 4328-4344.	1.2	30
423	Fine-needle aspiration for nucleic acid-based molecular analyses in breast cancer. <i>Cancer Cytopathology</i> , 2009, 117, 32-39.	1.4	15
424	Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects. <i>Supportive Care in Cancer</i> , 2009, 17, 839-845.	1.0	28
425	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1-dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009, 15, 1170-1178.	15.2	1,614
426	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 381-390.	5.1	55
427	Neoadjuvant chemotherapy for breast cancers: Current recommendations and future directions. <i>European Journal of Cancer</i> , 2009, 45, 368-370.	1.3	3
428	Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15. <i>PLoS ONE</i> , 2009, 4, e4942.	1.1	352
429	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 183-190.	1.1	85
430	Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. <i>British Journal of Cancer</i> , 2008, 99, 68-71.	2.9	39
431	Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. <i>BMC Bioinformatics</i> , 2008, 9, 149.	1.2	17
432	Evaluation of biological pathways involved in chemotherapy response in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R37.	2.2	53

#	ARTICLE	IF	CITATIONS
433	Gene expression predictors in breast cancer: Current status, limitations and perspectives. <i>European Journal of Cancer</i> , 2008, 44, 2714-2720.	1.3	52
434	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1275-1281.	0.8	2,387
435	Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. <i>Annals of Oncology</i> , 2008, 19, 1402-1406.	0.6	14
436	p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. <i>Annals of Oncology</i> , 2008, 19, 1261-1265.	0.6	53
437	Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4679-4683.	0.8	30
438	Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. <i>Annals of Oncology</i> , 2008, 19, 315-320.	0.6	31
439	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008, 19, 1875-1881.	0.6	45
440	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001.	3.9	520
441	Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 2636-2643.	0.8	54
442	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. <i>Journal of Clinical Oncology</i> , 2007, 25, 2650-2655.	0.8	253
443	Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1793-1798.	0.6	37
444	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. <i>Annals of Oncology</i> , 2007, 18, 1477-1483.	0.6	73
445	Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 "triple-negative" breast cancers. <i>Annals of Oncology</i> , 2007, 18, 1285-1286.	0.6	67
446	Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , 2007, 13, 3892-3898.	3.2	73
447	What can breast cancer molecular sub-classification add to conventional diagnostic tools?. <i>Annals of Oncology</i> , 2007, 18, ix33-ix36.	0.6	6
448	Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2061-2067.	3.2	115
449	Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2007, 18, 874-880.	0.6	67
450	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , 2007, 25, 2735-2740.	0.8	107

#	ARTICLE	IF	CITATIONS
451	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology</i> , The, 2007, 8, 203-211.	5.1	175
452	Lésions bénignes du sein et risque de transformation maligne : le point de vue de l'oncologue aujourd'hui. <i>Imagerie De La Femme</i> , 2007, 17, 119-123.	0.0	0
453	Gene-Expression Biomarkers as Predictors of Recurrence and Treatment-Related Outcomes in Breast Cancer. <i>Breast Diseases</i> , 2007, 18, 133-135.	0.0	1
454	D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC. <i>Journal of Thoracic Oncology</i> , 2007, 2, S397-S398.	0.5	7
455	PD2-3-4: Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, S444-S445.	0.5	5
456	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. <i>Cancer</i> , 2007, 109, 496-501.	2.0	41
457	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	15.2	2,657
458	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	2.8	491
459	DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 983-991.	13.9	1,611
460	Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy. <i>Pharmaceutical Research</i> , 2006, 23, 1951-1958.	1.7	11
461	DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 197-204.	3.3	16
462	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006, 80, 471-478.	1.5	117
463	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 621-632.	4.3	116
464	Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. <i>Annals of Oncology</i> , 2006, 17, 945-951.	0.6	167
465	Management of Extensive Small-Cell Lung Cancer. , 2006, , 371-376.		0
466	Chemoprevention of Lung Cancer. <i>Recent Results in Cancer Research</i> , 2005, 166, 145-165.	1.8	2
467	Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. <i>Annals of Oncology</i> , 2005, 16, 1846-1847.	0.6	82
468	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8331-8339.	0.8	266

#	ARTICLE	IF	CITATIONS
469	Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2996-3000.	0.8	27
470	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 737-747.	1.4	42
471	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 111-115.	0.6	37
472	Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. <i>European Journal of Cancer</i> , 2005, 41, 2112-2119.	1.3	27
473	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. <i>Journal of Translational Medicine</i> , 2005, 3, 10.	1.8	993
474	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. <i>Journal of Clinical Oncology</i> , 2004, 22, 3302-3308.	0.8	389
475	Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. <i>Annals of Oncology</i> , 2004, 15, 613-617.	0.6	198
476	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection. <i>Journal of Immunology</i> , 2004, 172, 2137-2146.	0.4	233
477	Her2-neu: a target in lung cancer?. <i>Annals of Oncology</i> , 2004, 15, 3-4.	0.6	46
478	Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class II/Peptide Complexes to Dendritic Cells. <i>Journal of Immunology</i> , 2004, 172, 2126-2136.	0.4	424
479	Risk factors for brain relapse in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1640-1644.	0.6	140
480	Exosomes for cancer immunotherapy. <i>Annals of Oncology</i> , 2004, 15, iv141-iv144.	0.6	81
481	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 234-239.	2.0	113
482	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. <i>Cancer</i> , 2004, 101, 918-925.	2.0	62
483	Exosomes for Immunotherapy of Cancer. , 2004, , 331-340.		1
484	A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 55-61.	0.9	190
485	Exosomes for Immunotherapy of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2003, 532, 215-221.	0.8	46
486	Malignant effusions and immunogenic tumour-derived exosomes. <i>Lancet, The</i> , 2002, 360, 295-305.	6.3	822

#	ARTICLE	IF	CITATIONS
487	Magnetic minerals as indicators of major environmental change in holocene black sea sediments: preliminary results. <i>Physics and Chemistry of the Earth</i> , 2002, 27, 1363-1370.	1.2	19
488	Tumor-derived exosomes: a new source of tumor rejection antigens. <i>Vaccine</i> , 2002, 20, A28-A31.	1.7	179
489	Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy. <i>Cancer</i> , 2001, 91, 2394-2400.	2.0	126
490	Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors. <i>British Journal of Cancer</i> , 2001, 84, 903-909.	2.9	62
491	Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 122, 796-802.	0.4	124
492	Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells. <i>Journal of Immunology</i> , 2001, 167, 1795-1802.	0.4	65
493	Persistence of viable tumor cells after radiation and chemotherapy for stage IIIB non-small cell lung cancer: An early marker of treatment failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 403-403.	0.4	5
494	Survival of Patients With Resected N2 Non-small-Cell Lung Cancer: Evidence for a Subclassification and Implications. <i>Journal of Clinical Oncology</i> , 2000, 18, 2981-2989.	0.8	472
495	Peritoneal Carcinomatosis in Germ-Cell Tumor. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 460-462.	0.6	4
496	The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. <i>European Journal of Cancer</i> , 2000, 36, 1389-1394.	1.3	211
497	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. <i>Journal of Clinical Oncology</i> , 1998, 16, 3736-3743.	0.8	109
498	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. <i>JCO Oncology Practice</i> , 0, , .	1.4	2